Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements review uncovered that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://adaml627bkp3.bmswiki.com/user